icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections
February 12-16, 2022
Back grey_arrow_rt.gif
B/F/TAF Five-Year Outcomes in Treatment-Naïve Adults
  CROI 2022 Feb 14-16
David A. Wohl,1 Anton Pozniak, Kimberly Workowski, Debbie Hagins, Eric S. Daar, Chloe Orkin, Ellen Koenig, Karam Mounzer, Samir Gupta, Hailin Huang, Rima K. Acosta, Jason Hindman, Jared Baeten, Hal Martin,10 Paul E. Sax11









References: 1. DHHS. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV; 12/18/19; 2. EACS Guidelines Version 10.0 November 2019; 3. Saag MS, et al. JAMA 2018;320:379-96; 4. Gallant J, et al. Lancet 2017;390:2063-72; 5. Orkin C, et al. Lancet HIV 2020;7:e389-400; 6. Sax PE, et al. Lancet 2017;390:2073-82; 7. Stellbrink H-J, et al. Lancet HIV 2019;6:e364-72; 8. Wohl DA, et al. Lancet HIV 2019;6:e355-63; 9. Custodio JM, et al. IDWeek 2017, poster 1386; 10. Hill JO, et al. Science 2003;299:853-5; 11. Lakey W, et al. AIDS Res Hum Retroviruses 2013;29:435-40; 12. Sax PE, et al. Clin Infect Dis 2020;71:1379-89; 13. Sharma A, et al. PLoS One 2015;10:e0143740; 14. Taramasso L, et al. Open Forum Infect Dis 2017;4:ofx239; 15. Tate T, et al. Antivir Ther 2012;17:1281-9; 16. Yuh B, et al. Clin Infect Dis 2015;60:1852-9. Acknowledgments: We extend our thanks to the participants, their partners and families, and all 1489 and 1490 investigators. Special thanks to the 1489 and 1490 study teams. These studies were funded by Gilead Sciences, Inc. Editorial and production assistance were provided by BioScience Communications, New York, NY, funded by Gilead